(Q86821073)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IκB and NFκB (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Ahmad Samer Al-Homsi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Zhongbin Lai

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Tara S Roy

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Nicholas Kouttab

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Richard P Junghans

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

19 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

published in

Transplant Immunology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

40-45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

cites work

Edward Donnall Thomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Hematopoietic-cell transplantation at 50.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Immunobiology of allogeneic hematopoietic stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

High-dose cyclophosphamide for graft-versus-host disease prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Antigen presentation by murine dendritic cells is nuclear factor-kappa B dependent both in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Pathophysiology of acute graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Acute graft-versus-host disease: from the bench to the bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Role of dendritic cells in graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Effect of novel proteasome and immunoproteasome inhibitors on dendritic cell maturation, function, and expression of IκB and NFκB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

The NF-kappa B and I kappa B proteins: new discoveries and insights

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.11.003

10.1016/J.TRIM.2013.11.003

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262132%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference